The newest records in the public change feed. Each links to its CMS document. The full shelf, by policy and contractor, is the corpus.
Federal Register Proposed Rule: Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Ap
CMS proposes Part D LIS cost-sharing, PBM accountability, and provider directory
FDA Approval: HOVILPR (PRITELIVIR) — Type 1 - New Molecular Entity
Oral pritelivir routes to Part D; no J-code expected.
FDA Approval: ISOVUE READI (IOPAMIDOL) — Type 5 - New Formulation or New Manufacturer
Oral iopamidol reformulation follows Part D, not Part B injectable path.
FDA Approval: ATNAA ATROPINE AND PRALIDOXIME CHLORIDE AUTO-INJECTOR (ATROPINE AND PRALIDOXIME CHLORIDE) — Type 3 - New D
IM nerve agent antidote auto-injector bills under Medicare Part B.
FDA Approval: VELPHORO (SUCROFERRIC OXYHYDROXIDE) — Type 5 - New Formulation or New Manufacturer
Oral phosphate binder for dialysis patients routes through Part D.
FDA Approval: PARAGARD T 380A (COPPER) — Type 3 - New Dosage Form
Copper IUD with Part D pathway; verify Medicare contraceptive coverage rules.
Showing the newest records. The complete, filterable shelf is on /corpus; dated changes by effective date are on /changes.
From the CLV research desk
Public, source-linked records built from the same pipeline that powers these alerts. Free to read and free to cite.